Abaxis (ABAX) 10-Q 12 Nov 13 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'ABAXIS INC	'
Entity Central Index Key	'0000881890	'
Current Fiscal Year End Date	'--03-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	22,271,000
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$71,446	$54,910
Short-term investments	14,447	23,354
Receivables (net of allowances of $210 at September 30, 2013 and $319 at March 31, 2013)	35,127	40,005
Inventories	27,368	26,786
Prepaid expenses and other current assets	5,808	3,319
Net deferred tax assets, current	4,909	4,589
Total current assets	159,105	152,963
Long-term investments	17,969	17,000
Investment in unconsolidated affiliate	2,629	2,613
Property and equipment, net	25,859	25,330
Intangible assets, net	2,373	3,122
Net deferred tax assets, non-current	649	643
Other assets	81	92
Total assets	208,665	201,763
Current liabilities:	'	'
Accounts payable	7,001	8,123
Accrued payroll and related expenses	5,507	6,261
Accrued taxes	433	440
Other accrued liabilities	2,378	2,838
Deferred revenue	1,235	1,362
Warranty reserve	872	995
Total current liabilities	17,426	20,019
Non-current liabilities:	'	'
Deferred rent	751	729
Deferred revenue	4,412	3,750
Warranty reserve	741	389
Notes payable, less current portion	632	682
Total non-current liabilities	6,536	5,550
Total liabilities	23,962	25,569
Commitments and contingencies (Note 9)	'	'
Shareholders' equity:	'	'
Preferred stock, no par value: 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, no par value: 35,000,000 shares authorized; 22,320,000 and 22,120,000 shares issued and outstanding at September 30, 2013 and at March 31, 2013, respectively	122,311	121,019
Retained earnings	62,358	55,133
Accumulated other comprehensive income	34	42
Total shareholders' equity	184,703	176,194
Total liabilities and shareholders' equity	$208,665	$201,763

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Receivables, allowances	$210	$319
Shareholders' equity:	'	'
Preferred stock, par value (in dollars per share)	$0	$0
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0	$0
Common stock, shares authorized (in shares)	35,000,000	35,000,000
Common stock, shares issued (in shares)	22,320,000	22,120,000
Common stock, shares outstanding (in shares)	22,320,000	22,120,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) [Abstract]	'	'	'	'
Revenues	$45,851	$44,258	$89,020	$86,272
Cost of revenues	23,979	21,135	46,256	40,300
Gross profit	21,872	23,123	42,764	45,972
Operating expenses:	'	'	'	'
Research and development	3,418	3,581	6,591	6,546
Sales and marketing	9,902	11,505	19,930	23,274
General and administrative	2,853	4,621	5,908	7,943
Gain from legal settlement	0	-17,250	0	-17,250
Total operating expenses	16,173	2,457	32,429	20,513
Income from operations	5,699	20,666	10,335	25,459
Interest and other income (expense), net	507	255	911	25
Income before income tax provision	6,206	20,921	11,246	25,484
Income tax provision	2,210	8,012	4,021	9,711
Net income	$3,996	$12,909	$7,225	$15,773
Net income per share:	'	'	'	'
Basic net income per share (in dollars per share)	$0.18	$0.59	$0.32	$0.72
Diluted net income per share (in dollars per share)	$0.18	$0.58	$0.32	$0.71
Shares used in the calculation of net income per share:	'	'	'	'
Weighted average common shares outstanding - basic (in shares)	22,306,000	21,920,000	22,268,000	21,869,000
Weighted average common shares outstanding - diluted (in shares)	22,574,000	22,306,000	22,589,000	22,280,000

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) [Abstract]	'	'	'	'
Net income	$3,996	$12,909	$7,225	$15,773
Other comprehensive income (loss):	'	'	'	'
Net change in unrealized gain (loss) on investments	8	44	-14	38
Provision (benefit) for income taxes related to items of other comprehensive income	3	18	-6	16
Other comprehensive income (loss), net of tax	5	26	-8	22
Comprehensive income	$4,001	$12,935	$7,217	$15,795

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income	$7,225	$15,773
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	3,584	2,916
Investment premium amortization, net	322	448
Net loss on disposals of property and equipment	6	20
Net (gain) loss on foreign exchange translation	-406	292
Share-based compensation expense	4,102	3,511
Excess tax benefits from share-based awards	-1,729	-1,145
Provision for deferred income taxes	-428	-303
Equity in net (income) loss of unconsolidated affiliate	-16	34
Changes in assets and liabilities:	'	'
Receivables, net	4,962	-17,691
Inventories	-1,174	-3,121
Prepaid expenses and other current assets	-699	3,988
Other assets	13	6
Accounts payable	-1,126	1,824
Accrued payroll and related expenses	-769	1,736
Accrued taxes	-17	3,700
Other accrued liabilities	-460	1,118
Deferred rent	22	50
Deferred revenue	535	585
Warranty reserve	229	-366
Net cash provided by operating activities	14,176	13,375
Cash flows from investing activities:	'	'
Purchases of held-to-maturity investments	-8,036	-13,961
Proceeds from maturities and redemptions of held-to-maturity investments	15,113	11,951
Proceeds from maturities and redemptions of available-for-sale investments	525	249
Purchases of property and equipment	-2,761	-2,945
Proceeds from disposals of property and equipment	9	0
Net cash provided by (used in) investing activities	4,850	-4,706
Cash flows from financing activities:	'	'
Proceeds from the exercise of stock options	26	261
Tax withholdings related to net share settlements of restricted stock units	-4,591	-1,495
Excess tax benefits from share-based awards	1,729	1,145
Net cash used in financing activities	-2,836	-89
Effect of exchange rate changes on cash and cash equivalents	346	-314
Net increase in cash and cash equivalents	16,536	8,266
Cash and cash equivalents at beginning of period	54,910	45,843
Cash and cash equivalents at end of period	71,446	54,109
Supplemental disclosure of cash flow information:	'	'
Cash paid for income taxes, net of refunds	4,006	3,308
Supplemental disclosure of non-cash flow information:	'	'
Change in unrealized gain (loss) on investments, net of tax	-8	22
Transfers of equipment between inventory and property and equipment, net	618	693
Net change in capitalized share-based compensation	26	35
Common stock withheld for employee taxes in connection with share-based compensation	4,591	1,495
Repayment of notes payable by credits from municipal agency	$50	$50

DESCRIPTION_OF_BUSINESS_AND_SI

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 1. DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
	Description of Business. Abaxis, Inc. (“Abaxis,” the “Company” or “we”), incorporated in California in 1989, develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. Abaxis provides veterinary reference laboratory diagnostic and consulting services for veterinarians. We conduct business worldwide and manage our business on the basis of the following two reportable segments: the medical market and the veterinary market.
	Abaxis Europe GmbH, our wholly-owned subsidiary in Darmstadt, Germany, markets, promotes and distributes diagnostic systems for medical and veterinary uses in the European market.
	Principles of Consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of Abaxis and our wholly-owned subsidiary, Abaxis Europe GmbH. Intercompany transactions and balances have been eliminated in consolidation.
	Basis of Presentation. We have prepared the unaudited condensed consolidated financial statements included herein pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim periods. The unaudited condensed consolidated financial statements included herein reflect all normal recurring adjustments, which are, in the opinion of our management, necessary to state fairly the results of operations and financial position for the periods presented. The results for the three and six month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the entire fiscal year ending March 31, 2014 or for any interim or future period.
	These unaudited condensed consolidated financial statements should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
	Reclassifications. Certain reclassifications have been made to prior periods’ financial statements to conform to the current period presentation, primarily related to segment categories (see Note 14, “Segment Reporting Information”). These reclassifications did not result in any change in previously reported net income, total assets or shareholders’ equity.
	Use of Estimates. The preparation of these condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period, and related disclosures. Such management estimates include allowance for doubtful accounts, sales and other allowances, estimated selling price of our products, fair value of investments, valuation of inventory, fair value and useful lives of intangible assets, income taxes, valuation allowance for deferred tax assets, share-based compensation and warranty reserves. Our management bases their estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Our actual results may differ materially from these estimates.
	Significant Accounting Policies. The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in our Annual Report on Form 10-K for the year ended March 31, 2013 filed with the SEC on June 14, 2013, and have not changed significantly since such filing.

RECENT_ACCOUNTING_PRONOUNCEMEN

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Sep. 30, 2013
RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]	'
RECENT ACCOUNTING PRONOUNCEMENTS	'
	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS
	Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income: In February 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income,” (Topic 220) - Comprehensive Income (“ASU 2013-02”), to amend existing rules to improve the reporting of reclassification out of accumulated other comprehensive income (“AOCI”). The amendment expands the existing disclosure by requiring entities to present information about significant items reclassified out of AOCI by component. In addition, an entity is required to provide information about the effects on net income of significant amounts reclassified out of each component of AOCI to net income either on the face of the statement where net income is presented or as a separate disclosure in the notes of the financial statements. We adopted ASU 2013-02 as of April 1, 2013. As this update only required additional disclosures, adoption of this amendment did not have a material impact on our financial position, results of operations and cash flows during the three and six months ended September 30, 2013.

INVESTMENTS

INVESTMENTS	6 Months Ended
	Sep. 30, 2013
INVESTMENTS [Abstract]	'
INVESTMENTS	'
	NOTE 3. INVESTMENTS
	Our investments are classified as either available-for-sale or held-to-maturity. The following table summarizes available-for-sale and held-to-maturity investments as of September 30, 2013 and March 31, 2013 (in thousands):
		Available-for-Sale Investments
				Gross		Gross
		Amortized		Unrealized		Unrealized			Fair
	30-Sep-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	996	$	3	$	-		$	999
	Corporate bonds		6,020		54		-			6,074
	Total available-for-sale investments	$	7,016	$	57	$	-		$	7,073
		Held-to-Maturity Investments
				Gross		Gross
		Amortized		Unrecognized		Unrecognized			Fair
	30-Sep-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	3,735	$	-	$	(5	)	$	3,730
	Corporate bonds		16,285		63		(16	)		16,332
	Municipal bonds		5,323		6		(67	)		5,262
	Total held-to-maturity investments	$	25,343	$	69	$	(88	)	$	25,324
		Available-for-Sale Investments
				Gross		Gross
		Amortized		Unrealized		Unrealized			Fair
	31-Mar-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	996	$	5	$	-		$	1,001
	Corporate bonds		6,029		65		-			6,094
	Municipal bonds		529		-		-			529
	Total available-for-sale investments	$	7,554	$	70	$	-		$	7,624
		Held-to-Maturity Investments
				Gross		Gross
		Amortized		Unrecognized		Unrecognized			Fair
	31-Mar-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	3,341	$	-	$	-		$	3,341
	Corporate bonds		16,284		121		(3	)		16,402
	Municipal bonds		13,105		32		(10	)		13,127
	Total held-to-maturity investments	$	32,730	$	153	$	(13	)	$	32,870
	The amortized cost of our held-to-maturity investments approximates their fair value. As of September 30, 2013 and March 31, 2013, we did not have other-than-temporary impairment in the fair value of any individual security classified as held-to-maturity or available-for-sale. As of September 30, 2013 and March 31, 2013, we had unrealized gains on available-for-sale investments, net of related income taxes of $34,000 and $42,000, respectively. During the three months ended September 30, 2013 and 2012, we did not have any redemptions of investments in accordance with callable provisions. During the six months ended September 30, 2013 and 2012, redemptions of investments in accordance with callable provisions were $623,000 and $717,000, respectively.
	The following table summarizes the amortized cost and fair value of our investments, classified by stated maturity as of September 30, 2013 and March 31, 2013 (in thousands):
		30-Sep-13				30-Sep-13
		Available-for-Sale Investments				Held-to-Maturity Investments
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
	Due in less than one year	$	996	$	999	$	13,448		$	13,474
	Due in 1 to 4 years		6,020		6,074		11,895			11,850
	Total investments	$	7,016	$	7,073	$	25,343		$	25,324
		31-Mar-13				31-Mar-13
		Available-for-Sale Investments				Held-to-Maturity Investments
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
	Due in less than one year	$	1,027	$	1,029	$	22,325		$	22,387
	Due in 1 to 4 years		6,527		6,595		10,405			10,483
	Total investments	$	7,554	$	7,624	$	32,730		$	32,870

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Sep. 30, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 4. FAIR VALUE MEASUREMENTS
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. When determining fair value, we consider the principal or most advantageous market in which we would transact and consider assumptions that market participants would use when pricing the asset or liability. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
	Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
	Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
	Level 3: Unobservable inputs that are supported by little or no market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions.
	The following table summarizes financial assets, measured at fair value on a recurring basis, by level within the fair value hierarchy as of September 30, 2013 and March 31, 2013 (in thousands):
		As of September 30, 2013
		Quoted Prices in		Significant		Significant
		Active Markets for		Other		Unobservable
		Identical Assets		Observable Inputs		Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	20,079	$	-	$	-	$	20,079
	Available-for-sale investments:
	Certificates of deposit		-		999		-		999
	Corporate bonds		-		6,074		-		6,074
	Total assets at fair value	$	20,079	$	7,073	$	-	$	27,152
		As of March 31, 2013
		Quoted Prices in		Significant		Significant
		Active Markets for		Other		Unobservable
		Identical Assets		Observable Inputs		Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	12,189	$	-	$	-	$	12,189
	Available-for-sale investments:
	Certificates of deposit		-		1,001		-		1,001
	Corporate bonds		-		6,094		-		6,094
	Municipal bonds		-		529		-		529
	Total assets at fair value	$	12,189	$	7,624	$	-	$	19,813
	As of September 30, 2013 and March 31, 2013, our Level 1 financial assets consisted of money market mutual funds. Our cash equivalents are highly liquid instruments with original or remaining maturities of three months or less at the time of purchase that are readily convertible into cash. The fair value of our Level 1 financial assets is based on quoted market prices of the underlying security. As of September 30, 2013 and March 31, 2013, we did not have any Level 1 financial liabilities.
	Our Level 2 financial assets primarily consist of certificates of deposit, corporate bonds and municipal bonds. We review trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy. As of September 30, 2013 and March 31, 2013, we did not have any Level 2 financial liabilities.
	As of September 30, 2013 and March 31, 2013, we did not have any Level 3 financial assets or liabilities measured at fair value on a recurring basis. During the three and six months ended September 30, 2013 and 2012, we did not have any Level 3 financial assets or liabilities measured at fair value on a recurring basis.

INVENTORIES

INVENTORIES	6 Months Ended
	Sep. 30, 2013
INVENTORIES [Abstract]	'
INVENTORIES	'
	NOTE 5. INVENTORIES
	Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or market. Components of inventories were as follows (in thousands):
		September 30,		March 31,
		2013		2013
	Raw materials	$	13,275	$	12,621
	Work-in-process		4,001		3,696
	Finished goods		10,092		10,469
	Inventories	$	27,368	$	26,786

INVESTMENT_IN_UNCONSOLIDATED_A

INVESTMENT IN UNCONSOLIDATED AFFILIATE	6 Months Ended
	Sep. 30, 2013
INVESTMENT IN UNCONSOLIDATED AFFILIATE [Abstract]	'
INVESTMENT IN UNCONSOLIDATED AFFILIATE	'
	NOTE 6. INVESTMENT IN UNCONSOLIDATED AFFILIATE
	Our investment in an unconsolidated affiliate consists of an investment in equity securities of Scandinavian Micro Biodevices APS (“SMB”). In February 2011, we purchased a 15% equity ownership interest in SMB, for $2.8 million in cash. SMB is a privately-held developer and manufacturer of point-of-care diagnostic products for veterinary use. SMB, based in Farum, Denmark, has been the original equipment manufacturer of the Abaxis VetScan VSpro point-of-care specialty analyzer since 2008. Abaxis has had exclusive distribution rights for the analyzer and associated cartridges in North America since 2008. Starting January 2011, Abaxis has non-exclusive rights in other areas of the world. We accounted for our investment in SMB using the equity method due to our significant influence over SMB’s operations. Our allocated portions of SMB’s net income (loss) during the three months ended September 30, 2013 and 2012 were $(14,000) and $(51,000), respectively, and during the six months ended September 30, 2013 and 2012 were $16,000 and $(34,000), respectively.

WARRANTY_RESERVES

WARRANTY RESERVES	6 Months Ended
	Sep. 30, 2013
WARRANTY RESERVES [Abstract]	'
WARRANTY RESERVES	'
	NOTE 7. WARRANTY RESERVES
	We provide for the estimated future costs to be incurred under our standard warranty obligation on our instruments and reagent discs.
	Instruments. Our standard warranty obligation on instruments ranges from one to three years, depending on the type of product. The estimated contractual warranty obligation is recorded when the related revenue is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated. Cost of revenues reflects estimated warranty expense for instruments sold in the current period and any adjustments in estimated warranty expense for the installed base under our standard warranty obligation based on our quarterly evaluation of service experience. The estimated accrual for warranty exposure is based on historical experience as to product failures, estimated product failure rates, estimated repair costs, material usage and freight incurred in repairing the instrument after failure and known design changes under the warranty plan. Management periodically evaluates the sufficiency of the warranty provisions and makes adjustments when necessary. If an unusual performance rate related to warranty claims is noted, an additional warranty accrual may be assessed and recorded when a failure event is probable and the cost can be reasonably estimated.
	Reagent Discs. We record a provision for defective reagent discs when the related sale is recognized and any additional amount is recorded when such cost is probable and can be reasonably estimated. The warranty cost includes the replacement costs and freight of a defective reagent disc. The balance of accrued warranty reserve related to replacement of defective reagent discs at September 30, 2013 and March 31, 2013 was $500,000 and $571,000, respectively, which was classified as a current liability on the condensed consolidated balance sheets.
	We evaluate our estimates for warranty reserves on an ongoing basis and believe we have the ability to reasonably estimate warranty costs. However, unforeseeable changes in factors may impact the estimate for warranty and such changes could cause a material change in our warranty reserve accrual in the period in which the change was identified.
	The change in our accrued warranty reserve during the three and six months ended September 30, 2013 and 2012 is summarized as follows (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Balance at beginning of period	$	1,327		$	1,494		$	1,384		$	1,846
	Provision for warranty expense		672			354			999			661
	Warranty costs incurred		(386	)		(368	)		(770	)		(737	)
	Adjustment to pre-existing warranties		-			-			-			(290	)
	Balance at end of period		1,613			1,480			1,613			1,480
	Non-current portion of warranty reserve		741			437			741			437
	Current portion of warranty reserve	$	872		$	1,043		$	872		$	1,043

BORROWINGS

BORROWINGS	6 Months Ended
	Sep. 30, 2013
BORROWINGS [Abstract]	'
BORROWINGS	'
	NOTE 8. BORROWINGS
	Notes Payable. We have a ten year loan agreement with the Community Redevelopment Agency of the City of Union City (“the Agency”) whereby the Agency provides us with an unsecured loan of up to $1.0 million, primarily to purchase capital equipment. The loan was effective January 2011, bears interest at 5.0% and is payable quarterly. As of September 30, 2013, our short-term and long-term notes payable balances were $100,000 and $632,000, respectively, and we recorded the short-term balance in “Other accrued liabilities” on the condensed consolidated balance sheets. The entire outstanding balance of the note is payable in full on the earlier of: (i) December 2020, or (ii) the date Abaxis ceases operations in Union City, California. The Agency also has the right to accelerate the maturity date and declare all balances immediately due and payable upon the event of default as defined in the loan agreement. We evaluate covenants in our loan agreement on a quarterly basis, and we were in compliance with such covenants as of September 30, 2013.
	In accordance with the terms of the loan agreement, the Agency will provide Abaxis with an annual credit that can be applied against the accrued interest and outstanding principal balance on a quarterly basis. The Agency determines the annual credit based on certain taxes paid by Abaxis to the City of Union City, California for a specified period, as defined in the loan agreement. We anticipate that our annual credits from the Agency will be used to fully repay our notes payable due to the Agency. We may carry forward unused quarterly credits to apply against our outstanding balance in a future period. Credits applied to repay our notes payable and accrued interest are recorded in “Interest and other income (expense), net” on the condensed consolidated statements of income.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Sep. 30, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 9. COMMITMENTS AND CONTINGENCIES
	Purchase Commitments. We have purchase commitments, comprising of supply and inventory related agreements, totaling approximately $14.6 million as of September 30, 2013. These purchase order commitments include our purchase obligations with SMB of Denmark to purchase VSpro specialty analyzers and related cartridges and Diatron MI PLC of Hungary to purchase Diatron hematology instruments.
	Patent Licensing Agreement. Effective January 2009, we entered into a license agreement with Alere. Under our license agreement, we licensed co-exclusively certain worldwide patent rights related to lateral flow immunoassay technology in the field of animal health diagnostics in the professional marketplace. The license agreement provides that Alere may not grant any future rights to any third parties under its current lateral flow patent rights in the animal health diagnostics field in the professional marketplace. The license agreement enables us to develop and market products under rights from Alere to address animal health and laboratory animal research markets.
	In exchange for the license rights, we (i) paid an up-front license fee of $5.0 million to Alere in January 2009, (ii) agreed to pay royalties during the term of the agreement, based solely on sales of products in a jurisdiction country covered by valid and unexpired claims in that jurisdiction under the licensed Alere patent rights, and (iii) agreed to pay a yearly minimum license fee of between $500,000 to $1.0 million per year, which fee will be creditable against any royalties due during such calendar year. The royalties, if any, are payable through the date of the expiration of the last valid patent licensed under the agreement that includes at least one claim in a jurisdiction covering products we sell in that jurisdiction. The yearly minimum fees are payable for so long as we desire to maintain exclusivity under the agreement.
	Litigation. On June 28, 2010, we filed a patent infringement lawsuit against Cepheid. On September 24, 2012, the parties agreed to terminate all pending and future claims connected with the litigation in exchange for a one-time payment by Cepheid of $17.3 million, which we recognized as an offset to operating expenses during the second quarter of fiscal 2013.
	On October 1, 2012, St. Louis Police Retirement System, a purported shareholder of Abaxis, filed a lawsuit against certain officers and each of our directors in the United States District Court for the Northern District of California alleging, among other things, that the directors violated Section 14(a) of the Securities Exchange Act of 1934 and breached their fiduciary duties by allegedly failing to disclose material information in our 2010 proxy statement, breached their fiduciary duties by allegedly violating the terms of our 2005 Equity Incentive Plan, and breached their fiduciary duties by failing to disclose alleged material information in our 2012 proxy statement regarding (1) the events leading up to our proposal to amend the 2005 Equity Incentive Plan to eliminate the limit on the number of shares that may be issued pursuant to restricted stock units, and (2) the effects of the proposed amendment on certain settled and outstanding restricted stock units. The plaintiff seeks, among other things, damages, disgorgement and attorney’s fees. In addition, the plaintiff sought, and on October 23, 2012 the court issued, an order preliminarily enjoining our shareholder vote on Proposal 2 in our 2012 proxy statement, regarding an amendment to the 2005 Equity Incentive Plan, until such time as additional disclosures could be made. The Company filed with the SEC and mailed to shareholders supplemental proxy materials approved by the court, the injunction was lifted and our shareholders approved the proposal to amend our 2005 Equity Incentive Plan. The defendants have filed motions to dismiss the claims. On October 1, 2013, before the court ruled on the motions to dismiss, the parties notified the court that they had reached a settlement of the lawsuit. The parties are in the process of formalizing the settlement agreement. Among other things, the proposed settlement terms provide for the claims against the defendants to be dismissed with prejudice and for the release of certain known or unknown claims that have been or could have been brought later in the court arising out of the same allegations. Abaxis has agreed that if the proposed settlement terms are approved by the court, it will adopt certain corporate governance measures, such measures to be in effect for at least five years. If the parties are not able to agree on the amount of an attorney’s fee award to be paid to the plaintiff’s counsel, subject to approval by the court, Abaxis anticipates that plaintiff will petition the court for an attorney’s fee award. The settlement is not contingent on the payment of any attorney’s fee award. We believe that any attorney’s fees that would be awarded to plaintiff’s counsel would not have a material adverse effect on Abaxis, our consolidated financial position and results of operations.
	We are involved from time to time in various litigation matters in the normal course of business. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flows.

EQUITY_COMPENSATION_PLANS_AND_

EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION	6 Months Ended
	Sep. 30, 2013
EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION [Abstract]	'
EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION	'
	NOTE 10. EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION
	Equity Compensation Plan
	As of September 30, 2013, we have one equity incentive plan under which our equity securities are authorized for issuance to our employees, directors and consultants. Our share-based compensation plan is described below.
	2005 Equity Incentive Plan. Our 2005 Equity Incentive Plan (the “Equity Incentive Plan”) restated and amended our 1998 Stock Option Plan. The Equity Incentive Plan allows for the awards of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance cash awards, performance shares, performance units, deferred compensation awards or other share-based awards to employees, directors and consultants. As of September 30, 2013, the Equity Incentive Plan provided for the issuance of a maximum of 6,786,000 shares, of which 939,000 shares of common stock were then available for future issuance. Shares that are canceled or forfeited from an award and shares withheld in satisfaction of tax withholding obligations are again available for issue under the Equity Incentive Plan.
	Our current practice is to issue new shares of common stock from our authorized shares for share-based awards upon the exercise of stock options or vesting of restricted stock units.
	Share-Based Compensation
	The following table summarizes total share-based compensation expense, net of tax, related to restricted stock units during the three and six months ended September 30, 2013 and 2012, which is included in our condensed consolidated statements of income (in thousands, except per share data):
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Cost of revenues		$	298		$	222		$	552		$	445
	Research and development			215			254			582			554
	Sales and marketing			595			584			1,301			1,272
	General and administrative			745			649			1,667			1,240
	Share-based compensation expense before income taxes			1,853			1,709			4,102			3,511
	Income tax benefit			(633	)		(613	)		(1,401	)		(1,257	)
	Total share-based compensation expense after income taxes		$	1,220		$	1,096		$	2,701		$	2,254
	Net impact of share-based compensation on:
	Basic net income per share		$	0.05		$	0.05		$	0.12		$	0.1
	Diluted net income per share		$	0.05		$	0.05		$	0.12		$	0.1
	Share-based compensation has been classified in the condensed consolidated statements of income or capitalized on the condensed consolidated balance sheets in the same manner as cash compensation paid to employees. Capitalized share-based compensation costs at September 30, 2013 and March 31, 2013 were $177,000 and $151,000, respectively, which were included in inventories on our condensed consolidated balance sheets.
	Cash Flow Impact
	The accounting standard with respect to share-based payment requires cash flows resulting from excess tax benefits to be classified as a part of cash flows from financing activities. Excess tax benefits are realized tax benefits from tax deductions for exercised stock options and vested restricted stock units in excess of the deferred tax asset attributable to share-based compensation expense for such share-based awards. Excess tax benefits are considered realized when the tax deductions reduce taxes that otherwise would be payable. Excess tax benefits classified as a financing cash inflow for the three months ended September 30, 2013 and 2012 were $332,000 and $428,000, respectively, and for the six months ended September 30, 2013 and 2012 were $1.7 million and $1.1 million, respectively.
	Stock Options
	Prior to fiscal 2007, we granted stock option awards to employees and directors as part of our share-based compensation program. Option awards to consultants were insignificant. Options granted to employees and directors generally expire ten years from the grant date. Options granted to employees generally become exercisable over a period of four years based on cliff-vesting terms and continuous employment. Options granted to non-employee directors generally become exercisable over a period of one year based on monthly vesting terms and continuous service. We have not granted any stock options since the beginning of fiscal 2007. We have recognized compensation expense for stock options granted during the requisite service period of the stock option. As of September 30, 2013, we had no unrecognized compensation expense related to stock options granted.
	Stock Option Activity
	The following table summarizes information regarding options outstanding and options exercisable at September 30, 2013 and the changes during the six-month period then ended:
						Weighted			Weighted
						Average			Average			Aggregate
						Exercise			Remaining			Intrinsic
			Number of			Price			Contractual			Value
			Shares			Per Share			Life (Years)			(In thousands)
	Outstanding at March 31, 2013			72,000		$	20.5
	Granted			-			-
	Exercised			(3,000	)		10.07
	Canceled or forfeited			-			-
	Outstanding at September 30, 2013			69,000		$	20.89			0.55		$	1,483
	Vested and expected to vest at September 30, 2013			69,000		$	20.89			0.55		$	1,483
	Exercisable at September 30, 2013			69,000		$	20.89			0.55		$	1,483
	The aggregate intrinsic value in the table above represents the pre-tax intrinsic value, based on our closing stock price as of September 30, 2013, of the shares that would have been received by the option holders had all option holders exercised their stock options as of that date. Total intrinsic value of stock options exercised during the three months ended September 30, 2013 and 2012 was $10,000 and $537,000, respectively, and during the six months ended September 30, 2013 and 2012 was $91,000 and $1.0 million, respectively. Cash proceeds from stock options exercised during the three months ended September 30, 2013 and 2012 were $9,000 and $184,000, respectively, and during the six months ended September 30, 2013 and 2012 were $26,000 and $261,000, respectively.
	Restricted Stock Units
	Since fiscal 2007, we have granted restricted stock unit awards to employees and directors as part of our share-based compensation program. Restricted stock unit awards to consultants have been insignificant. Awards of restricted stock units are issued at no cost to the recipient and may have time-based vesting criteria, or a combination of time-based and performance-based vesting criteria, as described below. From time to time, restricted stock unit awards granted to employees may be subject to accelerated vesting upon achieving certain performance-based milestones. Additionally, the Compensation Committee of our Board of Directors (the “Compensation Committee”) in its discretion, may provide in the event of a change in control for the acceleration of vesting and/or settlement of the restricted stock unit held by a participant upon such conditions and to such extent as determined by the Compensation Committee. Our Board of Directors has adopted an executive change in control severance plan, which it may terminate or amend at any time, that provides that awards granted to executive officers will accelerate fully on a change of control. The vesting of non-employee director and officer awards granted under the Equity Incentive Plan automatically will also accelerate in full upon a change in control.
	Restricted Stock Unit Awards (Time Vesting)
	Restricted stock unit awards with only time-based vesting terms, which we refer to as restricted stock unit awards (time vesting), entitle holders to receive shares of common stock at the end of a specified period of time. For restricted stock unit awards (time vesting), vesting is based on continuous employment or service of the holder. Upon vesting, the equivalent number of common shares are typically issued net of tax withholdings. If the service vesting conditions are not met, unvested restricted stock unit awards (time vesting) will be forfeited. Generally, restricted stock unit awards (time vesting) vest according to one of the following time-based vesting schedules:
	·	Restricted stock unit awards to employees: Four-year time-based vesting as follows: five percent vesting after the first year; additional ten percent after the second year; additional 15 percent after the third year; and the remaining 70 percent after the fourth year of continuous employment with the Company.
	·	Restricted stock unit awards to non-employee directors: 100 percent vesting after one year of continuous service to the Company.
	The fair value of restricted stock unit awards (time vesting) used in our expense recognition method is measured based on the number of shares granted and the closing market price of our common stock on the date of grant. Such value is recognized as an expense over the corresponding requisite service period. The share-based compensation expense is reduced for an estimate of the restricted stock unit awards that are expected to be forfeited. The forfeiture estimate is based on historical data and other factors, and compensation expense is adjusted for actual results. As of September 30, 2013, the total unrecognized compensation expense related to restricted stock unit awards (time vesting) granted amounted to $21.3 million, which is expected to be recognized over a weighted average service period of 1.9 years.
	Restricted Stock Unit Awards (Performance Vesting)
	We also began granting restricted stock unit awards subject to performance vesting criteria, which we refer to as restricted stock unit awards (performance vesting), to our executive officers starting in fiscal 2013. Restricted stock unit awards (performance vesting) consist of the right to receive shares of common stock, subject to achievement of time-based criteria and certain corporate performance-related goals over a specified period, as established by the Compensation Committee. For restricted stock units subject to performance vesting, we recognize any related share-based compensation expense ratably over the service period based on the most probable outcome of the performance condition. The fair value of our restricted stock unit awards (performance vesting) used in our expense recognition method is measured based on the number of shares granted, the closing market price of our common stock on the date of grant and an estimate of the probability of the achievement of the performance goals. The amount of share-based compensation expense recognized in any one period can vary based on the attainment or expected attainment of the performance goals. If such performance goals are not ultimately met, no compensation expense is recognized and any previously recognized compensation expense is reversed.
	In April 2012, the Compensation Committee approved the grant of restricted stock unit awards (performance vesting) for 84,000 shares of common stock to our executive officers that contained both time-based and performance-based vesting terms (the “FY2013 Performance RSUs”). The FY2013 Performance RSUs were subject to vesting in four equal annual increments based upon: (1) achievement of certain pre-established corporate annual performance-related goals, as established by the Compensation Committee; and (2) the grantee’s satisfaction of service requirements through the vesting period. The annual financial performance goals were established at the beginning of each performance period and, accordingly, the portion (or “tranche”) of the FY2013 Performance RSU subject to each goal is treated as a separate grant for accounting purposes. The number of vested restricted stock unit awards (performance vesting) is determined at the end of each annual performance period. The fiscal 2013 performance target for the FY2013 Performance RSUs was established at the grant date following ASC 718-10-55-95 and the aggregate estimated grant date fair value of the FY2013 Performance RSUs was $752,000, or $35.62 per share, based on the closing market price of our common stock on the date of grant. Only the target for fiscal 2013 performance for the first tranche was set in April 2012, and accordingly, only 25% of the FY2013 Performance RSUs were deemed granted in fiscal 2013 in accordance with ASC 718-10-55-95. In April 2013, the remaining 75% of the FY2013 Performance RSUs, which consisted of the second, third and fourth tranches, were cancelled as described below. The remaining 75% of the FY2013 Performance RSUs were not deemed granted for accounting purposes because each annual performance target was to be set at the start of each respective single-fiscal year performance period in accordance with ASC 718-10-55-95. We have recognized compensation expense for the FY2013 Performance RSUs during the requisite service period in fiscal 2013. As of September 30, 2013, we had no unrecognized compensation expenses related to FY2013 Performance RSUs.
	In April 2013, the Compensation Committee approved the grant of restricted stock unit awards (performance vesting) for 129,000 shares of common stock to our executive officers that also contained both time-based and performance-based vesting terms (the “FY2014 Performance RSUs”). The aggregate estimated grant date fair value of the FY2014 Performance RSUs was $5.5 million, or $42.43 per share, based on the closing market price of our common stock on the date of grant. The FY2014 Performance RSUs vest only if both of the following criteria are satisfied: (1) our consolidated income from operations for the fiscal year ending March 31, 2014, as certified by the Compensation Committee, is in excess of the applicable target amount set forth in the table below; and (2) the recipient remains in the Service of the Company (as defined in our Equity Incentive Plan) until the applicable vesting date set forth below:
	Shares Issuable Upon	Consolidated Income from
	Settlement of	Operations for the
	FY2014 Performance RSUs	Year Ending March 31, 2014	Vesting Date
	25%	> 90% of target	29-Apr-16
	25%	> 90% of target	29-Apr-17
	25%	> 100% of target	29-Apr-16
	25%	> 100% of target	29-Apr-17
	On April 29, 2013, 21,000 shares subject to the FY2013 Performance RSUs were issued to our executive officers as a result of achieving performance-related goals for the fiscal year ended March 31, 2013. In consideration of the grant of the FY2014 Performance RSUs described above, the remaining FY2013 Performance RSUs were cancelled and are no longer outstanding.
	As of September 30, 2013, we reviewed each of the underlying performance targets related to the outstanding FY2014 Performance RSUs and determined that it was not probable that the FY2014 Performance RSUs will vest as to 129,000 shares. Consequently, the compensation expense related to FY2014 Performance RSUs was reversed upon our determination of non-achievement of the performance metrics. We will assess the probability of achievement of the performance targets at the end of each quarter. If it becomes probable that the performance targets will be achieved, a cumulative adjustment will be recorded as if ratable share-based compensation expense had been recorded since the grant date. Additional share-based compensation of $676,000 would have been recorded during the six months ended September 30, 2013 for FY2014 Performance RSUs had the achievement of performance targets been deemed probable.
	Restricted Stock Unit Activity
	The following table summarizes restricted stock unit activity for the six months ended September 30, 2013:
			Time-Based Restricted						Performance-Based Restricted
		Stock Units						Stock Units
					Weighted						Weighted
					Average						Average
		Number of			Grant Date			Number of			Grant Date
		Shares			Fair Value(1)			Shares(2)			Fair Value(1)
Nonvested at March 31, 2013			980,000		$	26.42			21,000		$	35.62
Granted			161,000			41.8			129,000			42.43
Vested(3)			(285,000	)		21.54			(21,000	)		35.62
Canceled or forfeited			(11,000	)		30.65			-			-
Nonvested at September 30, 2013			845,000		$	30.95			129,000		$	42.43
-1	The weighted average grant date fair value of restricted stock units is based on the number of shares and the closing market price of our common stock on the date of grant.
-2	Nonvested shares at March 31, 2013 include only the FY2013 Performance RSUs that were deemed granted in accordance with ASC 718-10-55-95.
-3	The number of restricted stock units vested includes shares that we withheld on behalf of our employees to satisfy the statutory tax withholding requirements.
Total intrinsic value of restricted stock units vested during the three months ended September 30, 2013 and 2012 was $2.4 million and $1.8 million, respectively, and during the six months ended September 30, 2013 and 2012 was $12.9 million and $8.7 million, respectively. The total grant date fair value of restricted stock units vested during the three months ended September 30, 2013 and 2012 was $1.5 million and $1.1 million, respectively, and during the six months ended September 30, 2013 and 2012 was $6.9 million and $5.8 million, respectively.

SHAREHOLDERS_EQUITY

SHAREHOLDERS' EQUITY	6 Months Ended
	Sep. 30, 2013
SHAREHOLDERS' EQUITY [Abstract]	'
SHAREHOLDERS' EQUITY	'
	NOTE 11. SHAREHOLDERS’ EQUITY
	Share Repurchase Program
	Between August 2011 and January 2012, the Board of Directors authorized the repurchase of up to a total of $55.0 million of our common stock. In July 2013, the Board of Directors approved a $12.3 million increase to its existing share repurchase program to a total of $67.3 million. As of September 30, 2013, $40.0 million was available to purchase common stock. Since the share repurchase program began, through September 30, 2013, we have repurchased 1.2 million shares of our common stock at a total cost of $27.3 million. The repurchases are made from time to time on the open market at prevailing market prices or in negotiated transactions off the market. Repurchased shares are retired. During the three and six months ended September 30, 2013, we did not repurchase any of our common stock.
	Stock Purchase Rights
	On April 22, 2003, our Board of Directors approved the adoption of a Shareholder Rights Plan. Under the terms of the plan, shareholders of record on May 8, 2003, received one preferred stock purchase right for each outstanding share of common stock held. Each right entitled the registered holder to purchase from us one one-thousandth of a share of our Series RP Preferred Stock, $0.001 par value, at a price of $24.00 per share and would have become exercisable if a person or group acquired 15% or more of our common stock without prior approval by the Board of Directors.
	In addition, under certain conditions involving an acquisition or proposed acquisition, the rights permitted the holders (other than the acquirer) to purchase our common stock at a 50% discount from the market price at that time, and in the event of certain business combinations, the rights permitted the purchase of the common stock of an acquirer at a 50% discount from the market price at that time. Under certain conditions, the purchase rights would have been redeemed by the Board of Directors in whole, but not in part, at a price of $0.001 per right. The rights had no voting privileges and were attached to and automatically traded with our common stock.
	The Shareholder Rights Plan and rights granted thereunder expired in April 2013.
	Common Stock Warrants
	At September 30, 2013 and March 31, 2013, there were warrants to purchase 30,000 shares of common stock outstanding, of which 14,000 shares were vested, at a weighted average exercise price of $3.00 per share, expiring in fiscal years 2016 through 2017. The fair value of the warrants issued were determined using the Black-Scholes option-pricing model and are amortized over their estimated useful life, of approximately ten years, as an intangible asset. The warrants vest at a rate of 20% annually from their issuance dates and have a term of five years.

NET_INCOME_PER_SHARE

NET INCOME PER SHARE	6 Months Ended
	Sep. 30, 2013
NET INCOME PER SHARE [Abstract]	'
NET INCOME PER SHARE	'
	NOTE 12. NET INCOME PER SHARE
	Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding stock options, restricted stock units and warrants.
	The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net income per share (in thousands, except share and per share data):
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Numerator:
	Net income	$	3,996	$	12,909	$	7,225	$	15,773
	Denominator:
	Weighted average common shares outstanding - basic		22,306,000		21,920,000		22,268,000		21,869,000
	Weighted average effect of dilutive securities:
	Stock options		24,000		107,000		25,000		107,000
	Restricted stock units		216,000		252,000		268,000		277,000
	Warrants		28,000		27,000		28,000		27,000
	Weighted average common shares outstanding - diluted		22,574,000		22,306,000		22,589,000		22,280,000
	Net income per share:
	Basic net income per share	$	0.18	$	0.59	$	0.32	$	0.72
	Diluted net income per share	$	0.18	$	0.58	$	0.32	$	0.71
	Stock options and warrants are excluded from the computation of diluted weighted average shares outstanding if the exercise price of the stock options and warrants is greater than the average market price of our common stock during the period because the inclusion of these stock options and warrants would be antidilutive to net income per share. There were no stock options and warrants excluded from the computation of diluted weighted average shares outstanding during the three and six months ended September 30, 2013 and 2012.
	We excluded the following restricted stock units from the computation of diluted weighted average shares outstanding because the inclusion of these awards would be antidilutive to net income per share:
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Weighted average number of shares underlying antidilutive restricted stock units		-		-		-		101,000
	If the performance criteria for our restricted stock unit awards (performance vesting) are achieved, these awards will be considered outstanding for the purpose of computing diluted net income per share if the effect is dilutive. Because the performance criteria for these restricted stock unit awards (performance vesting) were not achieved during the three and six months ended September 30, 2013 and 2012, these awards were not included in the diluted net income per share calculation.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Sep. 30, 2013
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 13. INCOME TAXES
	During the three months ended September 30, 2013 and 2012, our income tax provision was $2.2 million, based on an effective tax rate of 36%, and $8.0 million, based on an effective tax rate of 38%, respectively. During the six months ended September 30, 2013 and 2012, our income tax provision was $4.0 million, based on an effective tax rate of 36%, and $9.7 million, based on an effective tax rate of 38%, respectively. The effective tax rates during the three and six months ended September 30, 2013, as compared to the three and six months ended September 30, 2012, decreased primarily due to (a) a discrete tax expense of approximately $6.7 million due to a gain from our legal settlement with Cepheid during the second quarter of fiscal 2013 and (b) reinstatement of federal research tax credits on January 2, 2013, partially offset by (c) an increase in non-deductible share-based compensation expense.
	We did not have any unrecognized tax benefits as of September 30, 2013 and March 31, 2013. During the three and six months ended September 30, 2013 and 2012, we did not recognize any interest or penalties related to unrecognized tax benefits.

SEGMENT_REPORTING_INFORMATION

SEGMENT REPORTING INFORMATION	6 Months Ended
	Sep. 30, 2013
SEGMENT REPORTING INFORMATION [Abstract]	'
SEGMENT REPORTING INFORMATION	'
	NOTE 14. SEGMENT REPORTING INFORMATION
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by our chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance.
	Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. We identify our reportable segments as those customer groups that represent more than 10% of our combined revenue or gross profit or loss of all reported operating segments. We manage our business on the basis of the following two reportable segments: (i) the medical market and (ii) the veterinary market, which are based on the products sold and services provided by market and customer group. For the products that we manufacture and sell, each reportable segment has similar manufacturing processes, technology and shared infrastructures. The accounting policies for segment reporting are the same as for the Company as a whole. We do not segregate assets by segments since our chief operating decision maker, or decision making group, does not use assets as a basis to evaluate a segment’s performance.
	Medical Market
	In the medical market reportable segment, we serve a worldwide customer group consisting of military installations (ships, field hospitals and mobile care units), physicians’ office practices across all specialties, urgent care, outpatient and walk-in clinics (free-standing or hospital-connected), health screening operations, home care providers (national, regional or local), nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies and hospital laboratories. Starting in the first quarter of fiscal 2013, we also began to serve the pharmaceutical clinical trial market. The products manufactured and sold in this segment primarily consist of Piccolo chemistry analyzers and medical reagent discs.
	Veterinary Market
	In the veterinary market reportable segment, we serve a worldwide customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. The products manufactured and sold in this segment primarily consist of VetScan chemistry analyzers and veterinary reagent discs. We also sell OEM supplied products in this segment consisting of VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i‑STAT analyzers and related VetScan i‑STAT consumables and rapid tests. Since October 2011, we have been providing veterinary reference laboratory diagnostic and consulting services for veterinarians in the United States through Abaxis Veterinary Reference Laboratories (“AVRL”), based in Olathe, Kansas.
	Total Revenues, Cost of Revenues and Gross Profit by Segment
	The table below summarizes revenues, cost of revenues and gross profit from our two operating segments and from certain unallocated items for the three and six months ended September 30, 2013 and 2012 (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
			2013		2012		2013		2012
	Revenues:
	Medical Market(1)		$	7,177	$	7,941	$	13,215	$	16,390
	Veterinary Market(1)			37,915		35,186		74,286		67,777
	Other(1)(2)			759		1,131		1,519		2,105
	Total revenues			45,851		44,258		89,020		86,272
	Cost of revenues:
	Medical Market(1)			3,999		3,658		7,293		7,401
	Veterinary Market(1)			19,961		17,442		38,909		32,822
	Other(1)(2)			19		35		54		77
	Total cost of revenues			23,979		21,135		46,256		40,300
	Gross profit:
	Medical Market(1)			3,178		4,283		5,922		8,989
	Veterinary Market(1)			17,954		17,744		35,377		34,955
	Other(1)(2)			740		1,096		1,465		2,028
	Gross profit		$	21,872	$	23,123	$	42,764	$	45,972
	-1	Includes certain prior period amounts by operating segment and unallocated items that were reclassified to conform to the current period presentation.
	-2	Represents unallocated items, not specifically identified to any particular business segment.

REVENUES_BY_PRODUCT_AND_SERVIC

REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS	6 Months Ended
	Sep. 30, 2013
REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS [Abstract]	'
REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS	'
	NOTE 15. REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS
	Revenue Information
	The following is a summary of our revenues by product and service category (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
	Revenues by Product and Service Category		2013		2012		2013		2012
	Instruments(1)		$	13,537	$	11,607	$	22,212	$	21,487
	Consumables(2)			28,699		29,412		59,298		58,894
	Other products and services(3)			3,577		3,202		7,435		5,816
	Product and service revenues, net			45,813		44,221		88,945		86,197
	Development and licensing revenue			38		37		75		75
	Total revenues		$	45,851	$	44,258	$	89,020	$	86,272
	-1	Instruments include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers.
	-2	Consumables include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests.
	-3	Other products and services include veterinary reference laboratory diagnostic and consulting services.
	The following is a summary of our revenues by geographic region based on customer location (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
	Revenues by Geographic Region		2013		2012		2013		2012
	North America		$	37,320	$	35,915	$	71,972	$	69,079
	Europe			6,446		6,493		12,998		13,709
	Asia Pacific and rest of the world			2,085		1,850		4,050		3,484
	Total revenues		$	45,851	$	44,258	$	89,020	$	86,272
	Significant Concentrations
	During the three months ended September 30, 2013, one distributor in the United States, MWI Veterinary Supply, accounted for 22% of our total worldwide revenues. During the three months ended September 30, 2012, one distributor in the United States, Animal Health International, accounted for 13% of our total worldwide revenues. During the six months ended September 30, 2013, one distributor in the United States, MWI Veterinary Supply, accounted for 22% of our total worldwide revenues. During the six months ended September 30, 2012, one distributor in the United States, Animal Health International, accounted for 13% of our total worldwide revenues.
	At September 30, 2013, two distributors in the United States accounted for 10% and 27%, respectively, of our total receivables balance. At March 31, 2013, two distributors in the United States accounted for 12% and 23%, respectively, of our total receivables balance.

DESCRIPTION_OF_BUSINESS_AND_SI1

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Sep. 30, 2013
DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of Abaxis and our wholly-owned subsidiary, Abaxis Europe GmbH. Intercompany transactions and balances have been eliminated in consolidation.
Basis of Presentation	'
	Basis of Presentation. We have prepared the unaudited condensed consolidated financial statements included herein pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim periods. The unaudited condensed consolidated financial statements included herein reflect all normal recurring adjustments, which are, in the opinion of our management, necessary to state fairly the results of operations and financial position for the periods presented. The results for the three and six month periods ended September 30, 2013 are not necessarily indicative of the results to be expected for the entire fiscal year ending March 31, 2014 or for any interim or future period.
	These unaudited condensed consolidated financial statements should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
Reclassifications	'
	Reclassifications. Certain reclassifications have been made to prior periods’ financial statements to conform to the current period presentation, primarily related to segment categories (see Note 14, “Segment Reporting Information”). These reclassifications did not result in any change in previously reported net income, total assets or shareholders’ equity.
Use of Estimates	'
	Use of Estimates. The preparation of these condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period, and related disclosures. Such management estimates include allowance for doubtful accounts, sales and other allowances, estimated selling price of our products, fair value of investments, valuation of inventory, fair value and useful lives of intangible assets, income taxes, valuation allowance for deferred tax assets, share-based compensation and warranty reserves. Our management bases their estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Our actual results may differ materially from these estimates.

INVESTMENTS_Tables

INVESTMENTS (Tables)	6 Months Ended
	Sep. 30, 2013
INVESTMENTS [Abstract]	'
Available-for-sale and held-to-maturity investments	'
	Our investments are classified as either available-for-sale or held-to-maturity.  The following table summarizes available-for-sale and held-to-maturity investments as of September 30, 2013 and March 31, 2013 (in thousands):
		Available-for-Sale Investments
				Gross		Gross
		Amortized		Unrealized		Unrealized			Fair
	30-Sep-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	996	$	3	$	-		$	999
	Corporate bonds		6,020		54		-			6,074
	Total available-for-sale investments	$	7,016	$	57	$	-		$	7,073
		Held-to-Maturity Investments
				Gross		Gross
		Amortized		Unrecognized		Unrecognized			Fair
	30-Sep-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	3,735	$	-	$	(5	)	$	3,730
	Corporate bonds		16,285		63		(16	)		16,332
	Municipal bonds		5,323		6		(67	)		5,262
	Total held-to-maturity investments	$	25,343	$	69	$	(88	)	$	25,324
		Available-for-Sale Investments
				Gross		Gross
		Amortized		Unrealized		Unrealized			Fair
	31-Mar-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	996	$	5	$	-		$	1,001
	Corporate bonds		6,029		65		-			6,094
	Municipal bonds		529		-		-			529
	Total available-for-sale investments	$	7,554	$	70	$	-		$	7,624
		Held-to-Maturity Investments
				Gross		Gross
		Amortized		Unrecognized		Unrecognized			Fair
	31-Mar-13	Cost		Gain		(Loss)			Value
	Certificates of deposit	$	3,341	$	-	$	-		$	3,341
	Corporate bonds		16,284		121		(3	)		16,402
	Municipal bonds		13,105		32		(10	)		13,127
	Total held-to-maturity investments	$	32,730	$	153	$	(13	)	$	32,870
Amortized cost and fair value of investments, classified by stated maturity	'
	The following table summarizes the amortized cost and fair value of our investments, classified by stated maturity as of September 30, 2013 and March 31, 2013 (in thousands):
		30-Sep-13				30-Sep-13
		Available-for-Sale Investments				Held-to-Maturity Investments
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
	Due in less than one year	$	996	$	999	$	13,448		$	13,474
	Due in 1 to 4 years		6,020		6,074		11,895			11,850
	Total investments	$	7,016	$	7,073	$	25,343		$	25,324
		31-Mar-13				31-Mar-13
		Available-for-Sale Investments				Held-to-Maturity Investments
		Amortized Cost		Fair Value		Amortized Cost			Fair Value
	Due in less than one year	$	1,027	$	1,029	$	22,325		$	22,387
	Due in 1 to 4 years		6,527		6,595		10,405			10,483
	Total investments	$	7,554	$	7,624	$	32,730		$	32,870

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Sep. 30, 2013
FAIR VALUE MEASUREMENTS [Abstract]	'
Financial Assets Measured at Fair Value on a Recurring Basis	'
	The following table summarizes financial assets, measured at fair value on a recurring basis, by level within the fair value hierarchy as of September 30, 2013 and March 31, 2013 (in thousands):
		As of September 30, 2013
		Quoted Prices in		Significant
		Active Markets		Other		Significant
		for Identical		Observable		Unobservable
		Assets		Inputs		Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	20,079	$	-	$	-	$	20,079
	Available-for-sale investments:
	Certificates of deposit		-		999		-		999
	Corporate bonds		-		6,074		-		6,074
	Total assets at fair value	$	20,079	$	7,073	$	-	$	27,152
		As of March 31, 2013
		Quoted Prices in		Significant
		Active Markets		Other		Significant
		for Identical		Observable		Unobservable
		Assets		Inputs		Inputs
		Level 1		Level 2		Level 3		Total
	Assets
	Cash equivalents	$	12,189	$	-	$	-	$	12,189
	Available-for-sale investments:
	Certificates of deposit		-		1,001		-		1,001
	Corporate bonds		-		6,094		-		6,094
	Municipal bonds		-		529		-		529
	Total assets at fair value	$	12,189	$	7,624	$	-	$	19,813

INVENTORIES_Tables

INVENTORIES (Tables)	6 Months Ended
	Sep. 30, 2013
INVENTORIES [Abstract]	'
Components of inventories	'
	Inventories include material, labor and overhead, and are stated at the lower of cost (first-in, first-out method) or market.  Components of inventories were as follows (in thousands):
		September 30,		March 31,
		2013		2013
	Raw materials	$	13,275	$	12,621
	Work-in-process		4,001		3,696
	Finished goods		10,092		10,469
	Inventories	$	27,368	$	26,786

WARRANTY_RESERVES_Tables

WARRANTY RESERVES (Tables)	6 Months Ended
	Sep. 30, 2013
WARRANTY RESERVES [Abstract]	'
Change in accrued warranty reserve	'
	The change in our accrued warranty reserve during the three and six months ended September 30, 2013 and 2012 is summarized as follows (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Balance at beginning of period	$	1,327		$	1,494		$	1,384		$	1,846
	Provision for warranty expense		672			354			999			661
	Warranty costs incurred		(386	)		(368	)		(770	)		(737	)
	Adjustment to pre-existing warranties		-			-			-			(290	)
	Balance at end of period		1,613			1,480			1,613			1,480
	Non-current portion of warranty reserve		741			437			741			437
	Current portion of warranty reserve	$	872		$	1,043		$	872		$	1,043

EQUITY_COMPENSATION_PLANS_AND_1

EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Sep. 30, 2013
EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION [Abstract]	'
Total share-based compensation expense, net of tax	'
	The following table summarizes total share-based compensation expense, net of tax, related to restricted stock units during the three and six months ended September 30, 2013 and 2012, which is included in our condensed consolidated statements of income (in thousands, except per share data):
			Three Months Ended						Six Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Cost of revenues		$	298		$	222		$	552		$	445
	Research and development			215			254			582			554
	Sales and marketing			595			584			1,301			1,272
	General and administrative			745			649			1,667			1,240
	Share-based compensation expense before income taxes			1,853			1,709			4,102			3,511
	Income tax benefit			(633	)		(613	)		(1,401	)		(1,257	)
	Total share-based compensation expense after income taxes		$	1,220		$	1,096		$	2,701		$	2,254
	Net impact of share-based compensation on:
	Basic net income per share		$	0.05		$	0.05		$	0.12		$	0.1
	Diluted net income per share		$	0.05		$	0.05		$	0.12		$	0.1
Stock option activity	'
	The following table summarizes information regarding options outstanding and options exercisable at September 30, 2013 and the changes during the six-month period then ended:
						Weighted			Weighted
						Average			Average			Aggregate
						Exercise			Remaining			Intrinsic
			Number of			Price			Contractual			Value
			Shares			Per Share			Life (Years)			(In thousands)
	Outstanding at March 31, 2013			72,000		$	20.5
	Granted			-			-
	Exercised			(3,000	)		10.07
	Canceled or forfeited			-			-
	Outstanding at September 30, 2013			69,000		$	20.89			0.55		$	1,483
	Vested and expected to vest at September 30, 2013			69,000		$	20.89			0.55		$	1,483
	Exercisable at September 30, 2013			69,000		$	20.89			0.55		$	1,483
Restricted Stock Unit Awards (Performance Vesting)	'
	In April 2013, the Compensation Committee approved the grant of restricted stock unit awards (performance vesting) for 129,000 shares of common stock to our executive officers that also contained both time-based and performance-based vesting terms (the “FY2014 Performance RSUs”).  The aggregate estimated grant date fair value of the FY2014 Performance RSUs was $5.5 million, or $42.43 per share, based on the closing market price of our common stock on the date of grant.  The FY2014 Performance RSUs vest only if both of the following criteria are satisfied:  (1) our consolidated income from operations for the fiscal year ending March 31, 2014, as certified by the Compensation Committee, is in excess of the applicable target amount set forth in the table below; and (2) the recipient remains in the Service of the Company (as defined in our Equity Incentive Plan) until the applicable vesting date set forth below:
	Shares Issuable Upon	Consolidated Income from
	Settlement of	Operations for the
	FY2014 Performance RSUs	Year Ending March 31, 2014	Vesting Date
	25%	> 90% of target	29-Apr-16
	25%	> 90% of target	29-Apr-17
	25%	> 100% of target	29-Apr-16
	25%	> 100% of target	29-Apr-17
Restricted stock unit activity	'
	The following table summarizes restricted stock unit activity for the six months ended September 30, 2013:
			Time-Based Restricted						Performance-Based Restricted
			Stock Units						Stock Units
						Weighted						Weighted
						Average						Average
			Number of			Grant Date			Number of			Grant Date
			Shares			Fair Value(1)			Shares(2)			Fair Value(1)
	Nonvested at March 31, 2013			980,000		$	26.42			21,000		$	35.62
	Granted			161,000			41.8			129,000			42.43
	Vested(3)			(285,000	)		21.54			(21,000	)		35.62
	Canceled or forfeited			(11,000	)		30.65			-			-
	Nonvested at September 30, 2013			845,000		$	30.95			129,000		$	42.43
	-1	The weighted average grant date fair value of restricted stock units is based on the number of shares and the closing market price of our common stock on the date of grant.
	-2	Nonvested shares at March 31, 2013 include only the FY2013 Performance RSUs that were deemed granted in accordance with ASC 718-10-55-95.
	-3	The number of restricted stock units vested includes shares that we withheld on behalf of our employees to satisfy the statutory tax withholding requirements.

NET_INCOME_PER_SHARE_Tables

NET INCOME PER SHARE (Tables)	6 Months Ended
	Sep. 30, 2013
NET INCOME PER SHARE [Abstract]	'
Reconciliation of weighted average number of common shares outstanding used in calculating basic and diluted net income per share	'
	The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net income per share (in thousands, except share and per share data):
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Numerator:
	Net income	$	3,996	$	12,909	$	7,225	$	15,773
	Denominator:
	Weighted average common shares outstanding - basic		22,306,000		21,920,000		22,268,000		21,869,000
	Weighted average effect of dilutive securities:
	Stock options		24,000		107,000		25,000		107,000
	Restricted stock units		216,000		252,000		268,000		277,000
	Warrants		28,000		27,000		28,000		27,000
	Weighted average common shares outstanding - diluted		22,574,000		22,306,000		22,589,000		22,280,000
	Net income per share:
	Basic net income per share	$	0.18	$	0.59	$	0.32	$	0.72
	Diluted net income per share	$	0.18	$	0.58	$	0.32	$	0.71
Antidilutive securities excluded from computation of diluted weighted average shares outstanding	'
	We excluded the following restricted stock units from the computation of diluted weighted average shares outstanding because the inclusion of these awards would be antidilutive to net income per share:
		Three Months Ended				Six Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Weighted average number of shares underlying antidilutive restricted stock units		-		-		-		101,000

SEGMENT_REPORTING_INFORMATION_

SEGMENT REPORTING INFORMATION (Tables)	6 Months Ended
	Sep. 30, 2013
SEGMENT REPORTING INFORMATION [Abstract]	'
Revenues, cost of revenues and gross profit, by Segment	'
	The table below summarizes revenues, cost of revenues and gross profit from our two operating segments and from certain unallocated items for the three and six months ended September 30, 2013 and 2012 (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
			2013		2012		2013		2012
	Revenues:
	Medical Market(1)		$	7,177	$	7,941	$	13,215	$	16,390
	Veterinary Market(1)			37,915		35,186		74,286		67,777
	Other(1)(2)			759		1,131		1,519		2,105
	Total revenues			45,851		44,258		89,020		86,272
	Cost of revenues:
	Medical Market(1)			3,999		3,658		7,293		7,401
	Veterinary Market(1)			19,961		17,442		38,909		32,822
	Other(1)(2)			19		35		54		77
	Total cost of revenues			23,979		21,135		46,256		40,300
	Gross profit:
	Medical Market(1)			3,178		4,283		5,922		8,989
	Veterinary Market(1)			17,954		17,744		35,377		34,955
	Other(1)(2)			740		1,096		1,465		2,028
	Gross profit		$	21,872	$	23,123	$	42,764	$	45,972
	-1	Includes certain prior period amounts by operating segment and unallocated items that were reclassified to conform to the current period presentation.
	-2	Represents unallocated items, not specifically identified to any particular business segment.

REVENUES_BY_PRODUCT_AND_SERVIC1

REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS (Tables)	6 Months Ended
	Sep. 30, 2013
REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS [Abstract]	'
Summary of revenues by product and service category	'
	The following is a summary of our revenues by product and service category (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
	Revenues by Product and Service Category		2013		2012		2013		2012
	Instruments(1)		$	13,537	$	11,607	$	22,212	$	21,487
	Consumables(2)			28,699		29,412		59,298		58,894
	Other products and services(3)			3,577		3,202		7,435		5,816
	Product and service revenues, net			45,813		44,221		88,945		86,197
	Development and licensing revenue			38		37		75		75
	Total revenues		$	45,851	$	44,258	$	89,020	$	86,272
	-1	Instruments include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers.
	-2	Consumables include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests.
	-3	Other products and services include veterinary reference laboratory diagnostic and consulting services.
Summary of revenues by geographic region	'
	The following is a summary of our revenues by geographic region based on customer location (in thousands):
			Three Months Ended				Six Months Ended
			September 30,				September 30,
	Revenues by Geographic Region		2013		2012		2013		2012
	North America		$	37,320	$	35,915	$	71,972	$	69,079
	Europe			6,446		6,493		12,998		13,709
	Asia Pacific and rest of the world			2,085		1,850		4,050		3,484
	Total revenues		$	45,851	$	44,258	$	89,020	$	86,272

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Amortized Cost	$7,016,000	'	$7,016,000	'	$7,554,000
Gross Unrealized Gain	57,000	'	57,000	'	70,000
Gross Unrealized (Loss)	0	'	0	'	0
Fair Value	7,073,000	'	7,073,000	'	7,624,000
Schedule of Held-to-maturity Securities [Line Items]	'	'	'	'	'
Amortized Cost	25,343,000	'	25,343,000	'	32,730,000
Gross Unrecognized Gain	69,000	'	69,000	'	153,000
Gross Unrecognized (Loss)	-88,000	'	-88,000	'	-13,000
Fair Value, Total investments	25,324,000	'	25,324,000	'	32,870,000
Available-for-sale Securities and Held-to-maturity Securities [Abstract]	'	'	'	'	'
Other-than-temporary impairment	0	'	0	'	0
Unrealized gain (loss) on available-for-sale investments, net of related income taxes	34,000	'	34,000	'	42,000
Redemptions of investments	0	0	623,000	717,000	'
Available-for-sale investments by stated maturity, amortized cost [Abstract]	'	'	'	'	'
Amortized Cost, Due in less than one year	996,000	'	996,000	'	1,027,000
Amortized Cost, Due in 1 to 4 years	6,020,000	'	6,020,000	'	6,527,000
Amortized Cost, Total investments	7,016,000	'	7,016,000	'	7,554,000
Available-for-sale investments by stated maturity, fair value [Abstract]	'	'	'	'	'
Fair Value, Due in less than one year	999,000	'	999,000	'	1,029,000
Fair Value, Due in 1 to 4 years	6,074,000	'	6,074,000	'	6,595,000
Fair Value, Total Investments	7,073,000	'	7,073,000	'	7,624,000
Held-to-maturity investments by stated maturity, amortized cost [Abstract]	'	'	'	'	'
Amortized Cost, Due in less than one year	13,448,000	'	13,448,000	'	22,325,000
Amortized Cost, Due in 1 to 4 years	11,895,000	'	11,895,000	'	10,405,000
Amortized Cost, Total investments	25,343,000	'	25,343,000	'	32,730,000
Held-to-maturity investments by stated maturity, fair value [Abstract]	'	'	'	'	'
Fair Value, Due in less than one year	13,474,000	'	13,474,000	'	22,387,000
Fair Value, Due in 1 to 4 years	11,850,000	'	11,850,000	'	10,483,000
Fair Value, Total investments	25,324,000	'	25,324,000	'	32,870,000
Certificates of Deposit [Member]	'	'	'	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'	'	'	'
Amortized Cost	3,735,000	'	3,735,000	'	3,341,000
Gross Unrecognized Gain	0	'	0	'	0
Gross Unrecognized (Loss)	-5,000	'	-5,000	'	0
Fair Value, Total investments	3,730,000	'	3,730,000	'	3,341,000
Held-to-maturity investments by stated maturity, fair value [Abstract]	'	'	'	'	'
Fair Value, Total investments	3,730,000	'	3,730,000	'	3,341,000
Corporate Bonds [Member]	'	'	'	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'	'	'	'
Amortized Cost	16,285,000	'	16,285,000	'	16,284,000
Gross Unrecognized Gain	63,000	'	63,000	'	121,000
Gross Unrecognized (Loss)	-16,000	'	-16,000	'	-3,000
Fair Value, Total investments	16,332,000	'	16,332,000	'	16,402,000
Held-to-maturity investments by stated maturity, fair value [Abstract]	'	'	'	'	'
Fair Value, Total investments	16,332,000	'	16,332,000	'	16,402,000
Municipal Bonds [Member]	'	'	'	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'	'	'	'
Amortized Cost	5,323,000	'	5,323,000	'	13,105,000
Gross Unrecognized Gain	6,000	'	6,000	'	32,000
Gross Unrecognized (Loss)	-67,000	'	-67,000	'	-10,000
Fair Value, Total investments	5,262,000	'	5,262,000	'	13,127,000
Held-to-maturity investments by stated maturity, fair value [Abstract]	'	'	'	'	'
Fair Value, Total investments	5,262,000	'	5,262,000	'	13,127,000
Certificates of Deposit [Member]	'	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Amortized Cost	996,000	'	996,000	'	996,000
Gross Unrealized Gain	3,000	'	3,000	'	5,000
Gross Unrealized (Loss)	0	'	0	'	0
Fair Value	999,000	'	999,000	'	1,001,000
Corporate Bonds [Member]	'	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Amortized Cost	6,020,000	'	6,020,000	'	6,029,000
Gross Unrealized Gain	54,000	'	54,000	'	65,000
Gross Unrealized (Loss)	0	'	0	'	0
Fair Value	6,074,000	'	6,074,000	'	6,094,000
Municipal Bonds [Member]	'	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'
Amortized Cost	'	'	'	'	529,000
Gross Unrealized Gain	'	'	'	'	0
Gross Unrealized (Loss)	'	'	'	'	0
Fair Value	'	'	'	'	$529,000

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Assets [Abstract]	'	'
Cash equivalents	$20,079	$12,189
Available-for-sale Investments [Abstract]	'	'
Certificates of deposit	999	1,001
Corporate bonds	6,074	6,094
Municipal bonds	'	529
Total assets at fair value	27,152	19,813
Quoted Prices in Active Markets for Identical Assets Level 1 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	20,079	12,189
Available-for-sale Investments [Abstract]	'	'
Certificates of deposit	0	0
Corporate bonds	0	0
Municipal bonds	'	0
Total assets at fair value	20,079	12,189
Significant Other Observable Inputs Level 2 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	0	0
Available-for-sale Investments [Abstract]	'	'
Certificates of deposit	999	1,001
Corporate bonds	6,074	6,094
Municipal bonds	'	529
Total assets at fair value	7,073	7,624
Significant Unobservable Inputs Level 3 [Member]	'	'
Assets [Abstract]	'	'
Cash equivalents	0	0
Available-for-sale Investments [Abstract]	'	'
Certificates of deposit	0	0
Corporate bonds	0	0
Municipal bonds	'	0
Total assets at fair value	$0	$0

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
INVENTORIES [Abstract]	'	'
Raw materials	$13,275	$12,621
Work-in-process	4,001	3,696
Finished goods	10,092	10,469
Inventories	$27,368	$26,786

INVESTMENT_IN_UNCONSOLIDATED_A1

INVESTMENT IN UNCONSOLIDATED AFFILIATE (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 28, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
INVESTMENT IN UNCONSOLIDATED AFFILIATE [Abstract]	'	'	'	'	'
Equity ownership interest purchased (in hundredths)	15.00%	'	'	'	'
Payment to acquire equity ownership interest in unconsolidated affiliate	$2,800,000	'	'	'	'
Allocated portion of unconsolidated affiliate's net income (loss)	'	($14,000)	($51,000)	$16,000	($34,000)

WARRANTY_RESERVES_Details

WARRANTY RESERVES (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013
					Instruments [Member]	Reagent Discs [Member]	Reagent Discs [Member]
Product Warranty Liability [Line Items]	'	'	'	'	'	'	'
Period of coverage for standard warranty obligation on instruments (in years)	'	'	'	'	'one to three	'	'
Change in accrued warranty reserve [Roll Forward]	'	'	'	'	'	'	'
Balance at beginning of period	$1,327,000	$1,494,000	$1,384,000	$1,846,000	'	'	'
Provision for warranty expense	672,000	354,000	999,000	661,000	'	'	'
Warranty costs incurred	-386,000	-368,000	-770,000	-737,000	'	'	'
Adjustment to pre-existing warranties	0	0	0	-290,000	'	'	'
Balance at end of period	1,613,000	1,480,000	1,613,000	1,480,000	'	'	'
Non-current portion of warranty reserve	741,000	437,000	741,000	437,000	'	'	'
Warranty reserve, balance at end of period	'	'	'	'	'	500,000	571,000
Current portion of warranty reserve	$872,000	$1,043,000	$872,000	$1,043,000	'	$500,000	$571,000

BORROWINGS_Details

BORROWINGS (Details) (USD $)	1 Months Ended	6 Months Ended
	Jan. 31, 2011	Sep. 30, 2013	Mar. 31, 2013
BORROWINGS [Abstract]	'	'	'
Term of loan agreement	'10 years	'	'
Face amount of debt	$1,000,000	'	'
Stated interest rate (in hundredths)	5.00%	'	'
Frequency of periodic payment	'Quarterly	'	'
Short-term notes payable	'	100,000	'
Notes payable, less current portion	'	$632,000	$682,000
Maturity date	'	31-Dec-20	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2009	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Purchase Commitment [Line Items]	'	'	'	'	'
Total purchase commitments	'	$14,600,000	'	$14,600,000	'
Patent Licensing Agreement [Abstract]	'	'	'	'	'
Payments for up-front license fee	5,000,000	'	'	'	'
Litigation [Abstract]	'	'	'	'	'
Gain related to litigation settlement	'	$0	$17,250,000	$0	$17,250,000
Minimum period for certain corporate governance measures to be adopted	'	'	'	'5 years	'
Minimum [Member]	'	'	'	'	'
Patent Licensing Agreement [Abstract]	'	'	'	'	'
Annual license fee	'	'	'	'between $500,000 to $1,000,000	'

EQUITY_COMPENSATION_PLANS_AND_2

EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Share-based compensation expense before income taxes	$1,853,000	$1,709,000	$4,102,000	$3,511,000	'
Income tax benefit	-633,000	-613,000	-1,401,000	-1,257,000	'
Total share-based compensation expense after income taxes	1,220,000	1,096,000	2,701,000	2,254,000	'
Net impact of share-based compensation on [Abstract]	'	'	'	'	'
Basic net income per share (in dollars per share)	$0.05	$0.05	$0.12	$0.10	'
Diluted net income per share (in dollars per share)	$0.05	$0.05	$0.12	$0.10	'
Capitalized share-based compensation costs	177,000	'	177,000	'	151,000
Excess tax benefits classified as financing cash inflow	332,000	428,000	1,729,000	1,145,000	'
2005 Equity Incentive Plan [Member]	'	'	'	'	'
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Maximum shares authorized for issuance (in shares)	6,786,000	'	6,786,000	'	'
Shares available for future issuance (in shares)	939,000	'	939,000	'	'
Cost of Revenues [Member]	'	'	'	'	'
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Share-based compensation expense before income taxes	298,000	222,000	552,000	445,000	'
Research and Development [Member]	'	'	'	'	'
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Share-based compensation expense before income taxes	215,000	254,000	582,000	554,000	'
Sales and Marketing [Member]	'	'	'	'	'
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Share-based compensation expense before income taxes	595,000	584,000	1,301,000	1,272,000	'
General and Administrative [Member]	'	'	'	'	'
Equity Compensation Plan and Allocation of Share-based Compensation [Line Items]	'	'	'	'	'
Share-based compensation expense before income taxes	$745,000	$649,000	$1,667,000	$1,240,000	'

EQUITY_COMPENSATION_PLANS_AND_3

EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION, Stock Options (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Term of grant	'	'	'10 years	'
Unrecognized compensation expense	$0	'	$0	'
Options, number of shares [Roll Forward]	'	'	'	'
Outstanding, beginning of period (in shares)	'	'	72,000	'
Granted (in shares)	'	'	0	'
Exercised (in shares)	'	'	-3,000	'
Canceled or forfeited (in shares)	'	'	0	'
Outstanding, end of period (in shares)	69,000	'	69,000	'
Vested and expected to vest, end of period (in shares)	69,000	'	69,000	'
Exercisable, end of period (in shares)	69,000	'	69,000	'
Options, average exercise price per share [Roll Forward]	'	'	'	'
Outstanding, beginning of period (in dollars per share)	'	'	$20.50	'
Granted (in dollars per share)	'	'	$0	'
Exercised (in dollars per share)	'	'	$10.07	'
Canceled or forfeited (in dollars per share)	'	'	$0	'
Outstanding, end of period (in dollars per share)	$20.89	'	$20.89	'
Vested and expected to vest, end of period (in dollars per share)	$20.89	'	$20.89	'
Exercisable, end of period (in dollars per share)	$20.89	'	$20.89	'
Additional disclosures [Abstract]	'	'	'	'
Outstanding, weighted average remaining contractual life	'	'	'6 months 18 days	'
Vested and expected to vest, weighted average remaining contractual life	'	'	'6 months 18 days	'
Exercisable, weighted average remaining contractual life	'	'	'6 months 18 days	'
Outstanding, aggregate intrinsic value	1,483,000	'	1,483,000	'
Vested and expected to vest, aggregate intrinsic value	1,483,000	'	1,483,000	'
Exercisable, aggregate intrinsic value	1,483,000	'	1,483,000	'
Total intrinsic value of stock options exercised	10,000	537,000	91,000	1,000,000
Proceeds from the exercise of stock options	$9,000	$184,000	$26,000	$261,000
Stock Options [Member] | Employees [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Award vesting period	'	'	'4 years	'
Stock Options [Member] | Non-Employee Directors [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Award vesting period	'	'	'1 year	'

EQUITY_COMPENSATION_PLANS_AND_4

EQUITY COMPENSATION PLANS AND SHARE-BASED COMPENSATION, Restricted Stock Units (Details) (USD $)

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Target/Service Condition One [Member]

Target/Service Condition Two [Member]

Target/Service Condition Three [Member]

Target/Service Condition Four [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Time-Based Restricted Stock Units [Member]

Time-Based Restricted Stock Units [Member]

Time-Based Restricted Stock Units [Member]

Performance RSUs [Member]

FY 2013 Performance RSUs [Member]

FY 2013 Performance RSUs [Member]

FY 2014 Performance RSUs [Member]

Employees [Member]

Non-Employee Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Time-based vesting schedules

'

'

'

'

'

'

'

'

'

'

'Four-year time-based vesting as follows: five percent vesting after the first year; additional ten percent after the second year; additional 15 percent after the third year; and the remaining 70 percent after the fourth year of continuous employment with the Company.

'100 percent vesting after one year of continuous service to the Company.

'

'

'

'

Vesting percentage after first year (in hundredths)

'

'

'

'

'

'

'

'

'

'

5.00%

100.00%

'

'

'

'

Additional vesting percentage after second year (in hundredths)

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

Additional vesting percentage after third year (in hundredths)

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

Additional vesting percentage after fourth year (in hundredths)

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

'

'

'

Shares not probable to vest (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

129,000

Unrecognized compensation expense

$0

'

'

'

'

'

'

'

'

$21,300,000

'

'

'

'

$0

'

Weighted average service period for recognition of unrecognized compensation costs

'

'

'

'

'

'

'

'

'

'1 year 10 months 24 days

'

'

'

'

'

'

Maximum shares authorized for issuance (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

84,000

'

129,000

Aggregate estimated grant date fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

752,000

'

5,500,000

Aggregate estimated grant date fair value (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$35.62

'

$42.43

Number of performance period

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

Percentage of restricted stock unit awards deemed granted each year

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

'

'

Percentage of restricted stock unit awards approved, but deemed not granted

'

'

'

'

'

'

'

'

'

'

'

'

'

75.00%

'

'

Performance target of restricted stock units by vesting date [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issuable Upon Settlement of FY2014 Performance RSUs (in hundredths)

'

0.25

0.25

0.25

0.25

'

'

'

'

'

'

'

'

'

'

'

Consolidated Income from Operations for the Year Ending March 31, 2014

'

'> 90% of target

'> 90% of target

'>100% of target

'> 100% of target

'

'

'

'

'

'

'

'

'

'

'

Vesting Date

'

29-Apr-16

29-Apr-17

29-Apr-16

29-Apr-17

'

'

'

'

'

'

'

'

'

'

'

Restricted Stock Unit Activity [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonvested, beginning of period (in shares)

'

'

'

'

'

'

'

'

'

980,000

'

'

21,000

[1]

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

161,000

'

'

129,000

[1]

'

'

'

Vested (in shares)

'

'

'

'

'

'

'

'

'

-285,000

[2]

'

'

-21,000

[1],[2]

'

'

'

Canceled or forfeited (in shares)

'

'

'

'

'

'

'

'

'

-11,000

'

'

0

[1]

'

'

'

Nonvested, end of period (in shares)

'

'

'

'

'

'

'

'

'

845,000

'

'

129,000

[1]

'

'

'

Restricted Stock Units Activity (in dollars per share) [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonvested, beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

'

$26.42

[3]

'

'

$35.62

[3]

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

$41.80

[3]

'

'

$42.43

[3]

'

'

'

Vested (in dollars per share)

'

'

'

'

'

'

'

'

'

$21.54

[2],[3]

'

'

$35.62

[2],[3]

'

'

'

Canceled or forfeited (in dollars per share)

'

'

'

'

'

'

'

'

'

$30.65

[3]

'

'

$0

[3]

'

'

'

Nonvested, end of period (in dollars per share)

'

'

'

'

'

'

'

'

'

$30.95

[3]

'

'

$42.43

[3]

'

'

'

Additional share based compensation that would have been recorded if performance targets had been deemed probable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

676,000

Total intrinsic value

'

'

'

'

'

2,400,000

1,800,000

12,900,000

8,700,000

'

'

'

'

'

'

'

Total grant date fair value

'

'

'

'

'

$1,500,000

$1,100,000

$6,900,000

$5,800,000

'

'

'

'

'

'

'

[1]

Nonvested shares at March 31, 2013 include only the FY2013 Performance RSUs that were deemed granted in accordance with ASC 718-10-55-95.

[2]

The number of restricted stock units vested includes shares that we withheld on behalf of our employees to satisfy the statutory tax withholding requirements.

[3]

The weighted average grant date fair value of restricted stock units is based on the number of shares and the closing market price of our common stock on the date of grant.

SHAREHOLDERS_EQUITY_Details

SHAREHOLDERS' EQUITY (Details) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended		1 Months Ended	6 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013	Jul. 31, 2013	Sep. 30, 2013	Mar. 31, 2013
					Share Repurchase Program [Member]	Share Repurchase Program [Member]	Share Repurchase Program [Member]
Share Repurchase Program [Abstract]	'	'	'	'	'	'	'
Authorized amount of stock repurchase	'	'	'	'	$67.30	$67.30	$55
Increase to existing share repurchase program	'	'	'	'	12.3	'	'
Stock repurchased and retired to date (in shares)	'	'	'	'	'	1,200,000	'
Stock repurchased and retired to date (value)	'	'	'	'	'	27.3	'
Share repurchases yet to be purchased under authorization	'	'	'	'	'	$40	'
Repurchase of common stock (in shares)	'	0	0	'	'	'	'
Stock Purchase Rights [Abstract]	'	'	'	'	'	'	'
Number of Preferred Stock Purchase Rights Issued for Each Outstanding Share of Common Stock (in shares)	1	'	'	'	'	'	'
Number of shares of Series RP Preferred Stock the holder of the Preferred Stock Purchase Right is entitled to (in shares)	0.001	'	'	'	'	'	'
Series RP Preferred Stock par value (in dollars per share)	$0.00	'	'	'	'	'	'
Share Price (in dollars per share)	$24	'	'	'	'	'	'
Percentage change in ownership that triggers the Preferred Stock Purchase Rights	15.00%	'	'	'	'	'	'
Percentage of discount from market value of common stock under certain set of circumstances	50.00%	'	'	'	'	'	'
Cash Value of the Purchase Right unit under certain circumstances (in dollars per share)	$0.00	'	'	'	'	'	'
Number of Votes per Preferred Stock Purchase Right	0	'	'	'	'	'	'
Common Stock Warrants [Abstract]	'	'	'	'	'	'	'
Warrants outstanding (in shares)	'	30,000	30,000	30,000	'	'	'
Warrants vested (in shares)	'	14,000	14,000	14,000	'	'	'
Weighted average exercise price (in dollars per share)	'	$3	$3	$3	'	'	'
Intangible asset useful life	'	'	'10 years	'	'	'	'
Annual vesting percentage (in hundredths)	'	'	20.00%	'	'	'	'
Warrants term	'	'	'5 years	'	'	'	'

NET_INCOME_PER_SHARE_Details

NET INCOME PER SHARE (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Numerator:	'	'	'	'
Net income	$3,996	$12,909	$7,225	$15,773
Denominator:	'	'	'	'
Weighted average common shares outstanding - basic (in shares)	22,306,000	21,920,000	22,268,000	21,869,000
Weighted average effect of dilutive securities:	'	'	'	'
Stock options (in shares)	24,000	107,000	25,000	107,000
Restricted stock units (in shares)	216,000	252,000	268,000	277,000
Warrants (in shares)	28,000	27,000	28,000	27,000
Weighted average common shares outstanding - diluted (in shares)	22,574,000	22,306,000	22,589,000	22,280,000
Net income per share:	'	'	'	'
Basic net income per share (in dollars per share)	$0.18	$0.59	$0.32	$0.72
Diluted net income per share (in dollars per share)	$0.18	$0.58	$0.32	$0.71
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number of shares underlying antidilutive securities (in shares)	0	0	0	101,000
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number of shares underlying antidilutive securities (in shares)	0	0	0	0
Warrants [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average number of shares underlying antidilutive securities (in shares)	0	0	0	0

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
INCOME TAXES [Abstract]	'	'	'	'	'
Income tax provision	$2,210,000	$8,012,000	$4,021,000	$9,711,000	'
Effective income tax rate (in hundredths)	36.00%	38.00%	36.00%	38.00%	'
Discrete tax expense due to gain from legal settlement	'	6,700,000	'	6,700,000	'
Unrecognized tax benefits	0	'	0	'	0
Penalties and interest expense related to unrecognized tax benefits	$0	$0	$0	$0	'

SEGMENT_REPORTING_INFORMATION_1

SEGMENT REPORTING INFORMATION (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
SEGMENT REPORTING INFORMATION [Abstract]	'		'		'		'
Minimum percentage of revenues or gross profit (loss) in order for customer group to be identified as reportable segment (in hundredths)	'		'		10.00%		'
Number of reportable segments	'		'		2		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	$45,851		$44,258		$89,020		$86,272
Cost of revenues	23,979		21,135		46,256		40,300
Gross profit	21,872		23,123		42,764		45,972
Medical Market [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	7,177	[1]	7,941	[1]	13,215	[1]	16,390	[1]
Cost of revenues	3,999	[1]	3,658	[1]	7,293	[1]	7,401	[1]
Gross profit	3,178	[1]	4,283	[1]	5,922	[1]	8,989	[1]
Veterinary Market [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	37,915	[1]	35,186	[1]	74,286	[1]	67,777	[1]
Cost of revenues	19,961	[1]	17,442	[1]	38,909	[1]	32,822	[1]
Gross profit	17,954	[1]	17,744	[1]	35,377	[1]	34,955	[1]
Other Market [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	759	[1],[2]	1,131	[1],[2]	1,519	[1],[2]	2,105	[1],[2]
Cost of revenues	19	[1],[2]	35	[1],[2]	54	[1],[2]	77	[1],[2]
Gross profit	$740	[1],[2]	$1,096	[1],[2]	$1,465	[1],[2]	$2,028	[1],[2]
[1]	Includes certain prior period amounts by operating segment and unallocated items that were reclassified to conform to the current period presentation.
[2]	Represents unallocated items, not specifically identified to any particular business segment.

REVENUES_BY_PRODUCT_AND_SERVIC2

REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS, Revenue by product and Services (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Revenue from External Customer [Line Items]	'		'		'		'
Product and service revenues, net	$45,813		$44,221		$88,945		$86,197
Development and licensing revenue	38		37		75		75
Total revenues	45,851		44,258		89,020		86,272
Instruments [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Product and service revenues, net	13,537	[1]	11,607	[1]	22,212	[1]	21,487	[1]
Consumables [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Product and service revenues, net	28,699	[2]	29,412	[2]	59,298	[2]	58,894	[2]
Other Products And Services [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Product and service revenues, net	$3,577	[3]	$3,202	[3]	$7,435	[3]	$5,816	[3]
[1]	Instruments include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers.
[2]	Consumables include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests.
[3]	Other products and services include veterinary reference laboratory diagnostic and consulting services.

REVENUES_BY_PRODUCT_AND_SERVIC3

REVENUES BY PRODUCT AND SERVICE CATEGORY AND GEOGRAPHIC REGION AND SIGNIFICANT CONCENTRATIONS (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Worldwide Revenues [Member]

Worldwide Revenues [Member]

Worldwide Revenues [Member]

Worldwide Revenues [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

North America [Member]

North America [Member]

North America [Member]

North America [Member]

Europe [Member]

Europe [Member]

Europe [Member]

Europe [Member]

Asia Pacific and Rest of the World [Member]

Asia Pacific and Rest of the World [Member]

Asia Pacific and Rest of the World [Member]

Asia Pacific and Rest of the World [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer

Customer

Customer

Customer

Customer

Customer

Leading percentage distributor for the period [Member]

Leading percentage distributor for the period [Member]

Next highest percentage distributor for the period [Member]

Next highest percentage distributor for the period [Member]

Revenues from External Customers [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total revenues

$45,851

$44,258

$89,020

$86,272

'

'

'

'

'

'

'

'

'

'

$37,320

$35,915

$71,972

$69,079

$6,446

$6,493

$12,998

$13,709

$2,085

$1,850

$4,050

$3,484

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of major customers

'

'

'

'

1

1

1

1

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue or accounts receivable by major customer

'

'

'

'

22.00%

13.00%

22.00%

13.00%

'

'

27.00%

23.00%

10.00%

12.00%

'

'

'

'

'

'

'

'

'

'

'

'